The Asia Pacific biologics contract manufacturing market is entering a high-growth phase, supported by rising biopharmaceutical demand, expanding biologics pipelines, and increasing outsourcing among small and virtual biotechnology companies. According to Transparency Market Research, the market is projected to reach US$9.8 billion by 2031, expanding at a 14.5% CAGR from 2021 to 2031. Growing...
